Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hazel Lote

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Frontiers in Oncology|December 14, 2023
MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patientsHazel Lote, Florentia Mousoullou, George Vlachogiannis, et al.
Urologic Oncology|December 17, 2015
Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy eraGwenaelle Gravis, Brice Chanez, Lisa Derosa, et al.
Carcinogenesis|July 7, 2016
Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patientsFrancesco Sclafani, Ian Chau, David Cunningham, et al.
Scientific Reports|January 25, 2018
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancerFrancesco Sclafani, Ian Chau, David Cunningham, et al.
British Journal of Cancer|November 2, 2016
MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinomaFrancesco Trevisani, Michele Ghidini, Alessandro Larcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2019
miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C TrialGayathri Anandappa, Andrea Lampis, David Cunningham, et al.
Gut|August 10, 2017
Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II studyKhurum Khan, Mihaela Rata, David Cunningham, et al.
Cancer Discovery|September 1, 2018
Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical TrialKhurum H Khan, David Cunningham, Benjamin Werner, et al.
Science (New York, N.Y.)|February 24, 2018
Patient-derived organoids model treatment response of metastatic gastrointestinal cancersGeorgios Vlachogiannis, Somaieh Hedayat, Alexandra Vatsiou, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Frontiers in Oncology|December 14, 2023
MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patientsHazel Lote, Florentia Mousoullou, George Vlachogiannis, et al.
Urologic Oncology|December 17, 2015
Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy eraGwenaelle Gravis, Brice Chanez, Lisa Derosa, et al.
Carcinogenesis|July 7, 2016
Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patientsFrancesco Sclafani, Ian Chau, David Cunningham, et al.
Scientific Reports|January 25, 2018
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancerFrancesco Sclafani, Ian Chau, David Cunningham, et al.
British Journal of Cancer|November 2, 2016
MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinomaFrancesco Trevisani, Michele Ghidini, Alessandro Larcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2019
miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C TrialGayathri Anandappa, Andrea Lampis, David Cunningham, et al.
Gut|August 10, 2017
Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II studyKhurum Khan, Mihaela Rata, David Cunningham, et al.
Cancer Discovery|September 1, 2018
Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical TrialKhurum H Khan, David Cunningham, Benjamin Werner, et al.
Science (New York, N.Y.)|February 24, 2018
Patient-derived organoids model treatment response of metastatic gastrointestinal cancersGeorgios Vlachogiannis, Somaieh Hedayat, Alexandra Vatsiou, et al.
Pageof 2